CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Intervention not reported
Clinical HINTS
1 finding from 1 review
Intervention not reported
Investigation of heterogeneity and sensitivity analyses
1 finding from 1 review
no estimate extracted
95 participants
Moderate
Intervention not reported
Conclusions
1 finding from 1 review
no estimate extracted
94 participants
GRADE not reported
Intervention not reported
Video‐assisted HINTS
1 finding from 1 review
Intervention not reported
Clinical HINTS Plus
1 finding from 1 review
Intervention not reported
Video‐assisted HINTS Plus
1 finding from 1 review
Intervention not reported
Secondary objectives for HINTS subcomponents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Nystagmus
1 finding from 1 review
Intervention not reported
Test of skew
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes dry eye symptoms, measured using the SPEED score at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
MD 0
Studies not reported
Very low
Incidence of adverse events at 3 months of · people with meibomian gland dysfunction
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Clinical signs—TBUT at 1 month (seconds) · people with meibomian gland dysfunction
IPL (with/without MGX) showed no clear difference in sodium fluorescein TBUT, measured in seconds, at 3 months of compared with sham or no treatment (with/without MGX) (low certainty).
1 finding from 1 review
MD 2.02
Studies not reported
Low
NIBUT, measured in seconds, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes NIBUT, measured in seconds, at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
MD 5.5
Studies not reported
Very low
Tear osmolarity, measured in mOsmol/L, at 3 months of · people with meibomian gland dysfunction
IPL (with/without MGX) showed no clear difference in tear osmolarity, measured in mOsmol/L, at 3 months of compared with sham or no treatment (with/without MGX) (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Meibomian gland orifice plugging, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes meibomian gland orifice plugging, at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Corneal sodium fluorescein staining, measured using a validated clinical scale, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes corneal sodium fluorescein staining, measured using a validated… compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low